Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.

Journal article

The optimal dose of interferon-alfa (IFN) for chronic myeloid leukemia (CML) is unknown. Retrospective analyses suggest that low doses are as effective as high doses, with less toxicity and fewer patients abandoning the drug. The Dutch Hemato-Oncology Association (HOVON) and British Medical Research Council (MRC) cooperative groups jointly performed randomized trials in newly diagnosed CML patients, comparing high-dose IFN (5 MIU/m(2) daily) with low-dose (3 MIU, 5 times a week). Both arms al...

Expand abstract

Authors: Kluin-Nelemans, H; Buck, G; le Cessie, S; Richards, S; Beverloo, H

• Publication status: Published
• Journal: Blood
• Volume: 103
• Issue: 12
• Pages: 4408-4415
• Publication date: 2004-06-01
• DOI: 10.1182/blood-2003-10-3605
• EISSN: 1528-0020
• ISSN: 0006-4971
• Language: English
• Keywords: Dose-Response Relationship, Drug; Middle Aged; Adult; Placebos; Humans; MRC and HOVON groups; Hydroxyurea; Survival Analysis; Adolescent; Cause of Death; Quality of Life; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents; Patient Compliance; Interferon-alpha